Avant Technologies INC

Avai Bio, Inc. and Ainnova Tech have mutually agreed to terminate their joint venture and dissolve Ai-Nova Acquisition Corp.

Avant Technologies, Inc. officially changed its name to AVAI BIO, INC. on February 3, 2026, while retaining its AVAI ticker symbol.

Avant Technologies Inc. has formed a 50/50 joint venture, Insulinova Inc., with biotech firm SGAustria Pte. Ltd. to develop diabetes treatments, committing up to $1.5 million in initial capital.

Avant Technologies Inc. has entered a joint venture with SGAustria Pte. Ltd. to form Klothonova Inc., focusing on cell-based treatments for age-related diseases.

Avant Technologies Inc. has filed an application with FINRA to change its corporate name to Ava Bio, Inc. to better reflect its current business.

Avant Technologies terminated its existing Equity Financing Agreement with GHS Investments, LLC, citing misalignment with current business objectives and shareholder interests, and plans to pursue a new agreement with improved terms.

Ava Bio, Inc. (formerly Avant Technologies Inc.) reported increased net losses for the quarter ended December 31, 2025, alongside a significant increase in liabilities and a strategic shift into biotech through new joint ventures.

Avant Technologies, soon to be Ava Bio, reported a reduced net loss for Q2 2026, signaling a strategic pivot towards biotech through new joint ventures while facing ongoing capital requirements and internal control deficiencies.

Avant Technologies Inc. reported a reduced net loss for Q1 2026, but faces significant liquidity challenges and a going concern doubt, relying on future capital raises for operations.

Avant Technologies Inc. reports no revenue for Q3 2025, focusing on AI acquisitions and strategic partnerships to drive future growth.

Avant Technologies Inc. has filed an amended quarterly report to correct an error in certifications related to internal control over financial reporting, while also providing an update on its financial status for the quarter ended September 30, 2024.

Avant Technologies has filed an amendment to its quarterly report to correct an error related to internal controls over financial reporting.

Avai Bio, Inc. (formerly Avant Technologies Inc.) filed its annual report on Form 10-K for the fiscal year ended March 31, 2026, detailing its AI technology focus, financial performance, and forward-looking strategies.

Avant Technologies Inc. reported a net loss of $1.14 million for fiscal year 2025, continuing its history of unprofitability and raising substantial doubt about its ability to continue as a going concern, despite strategic AI acquisitions and a planned pursuit of new financing.

Avant Technologies Inc. files an amendment to its annual report to correct unintentional errors in the Report of Independent Registered Public Accounting Firm.

Avant Technologies Inc. has filed an amendment to its annual report on Form 10-K to correct unintentional errors, including revisions to dates and updated officer certifications.

Avant Technologies Inc. reports its full year 2024 results, detailing strategic acquisitions in AI and IT consulting, alongside significant operating losses and a going concern warning.

Avant Technologies enters into an equity financing agreement with GHS Investments, potentially securing up to $20 million over 24 months through the sale of common stock.

Avant Technologies Inc. has filed a registration statement for the resale of up to 40,000,000 shares of its common stock by a selling stockholder.